Wilms’ tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation

Table 3 Multivariate analyses for 5-year outcomes in the total patients (n = 151)

Variables	HR (95% CI)	P value
Relapse
Cytogenetics and molecular abnormalities
Intermediate	1.00
Unfavorable	2.23 (1.05–4.75)	0.037^*
Disease status before allo-HSCT
CR1	1.00
CR2	1.93 (0.55–6.81)	0.306
NR	10.74 (3.25–35.47)	< 0.001^*
Donor type
ISD	1.00
URD	0.32 (0.04–2.82)	0.302
Haplo-RD	0.33 (0.12–0.90)	0.030^*
UCB	1.85 (0.35–9.86)	0.472
MRD status after allo-HSCT
MRD-	1.00
WT1+ alone	2.89 (1.25–6.71)	0.014^*
MRDco+	6.10 (2.09–17.78)	0.001^*
DFS
Cytogenetics and molecular abnormalities
Intermediate	1.00
Unfavorable	2.49 (1.32–4.72)	0.005^*
Disease status before allo-HSCT
CR1	1.00
CR2	1.48 (0.51–4.27)	0.471
NR	6.23 (2.06–18.81)	0.001^*
MRD status after allo-HSCT
MRD-	1.00
WT1+ alone	1.79 (0.88–3.65)	0.110
MRDco+	4.75 (2.00–11.29)	< 0.001^*
OS
Cytogenetics and molecular abnormalities
Intermediate	1.00
Unfavorable	2.42 (1.24–4.73)	0.010^*
MRD status after allo-HSCT
MRD-	1.00
WT1+ alone	1.59 (0.74–3.38)	0.232
MRDco+	5.62 (2.34–13.52)	< 0.001^*

CR Complete remission, NR No remission, ISD HLA-identical sibling donor, URD HLA-unrelated donor, Haplo-RD HLA-haploidentical related donor, UCB Umbilical cord blood, MRD- MRD negativity, WT1+ alone WT1 positivity alone, MRDco+ Combined MRD positivity, DFS Disease-free survival, OS Overall survival, HR Hazard ratio, CI Confidence interval
* means P < 0.05

ISSN: 1471-2407